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Abstract
Zinc ﬁngermotifs are distributed amongstmanyeukaryotic protein families, directing nucleic acid–protein and protein–protein
interactions. Zinc ﬁnger protein 106 (ZFP106) has previously been associated with roles in immune response, muscle
differentiation, testes development andDNAdamage, although little is known about its speciﬁc function. To further investigate
the function of ZFP106, we performed an in-depth characterization of Zfp106 deﬁcient mice (Zfp106−/−), and we report a novel
role for ZFP106 in motor and sensory neuronal maintenance and survival. Zfp106−/−mice develop severe motor abnormalities,
major deﬁcits in muscle strength and histopathological changes in muscle. Intriguingly, despite being highly expressed
throughout the central nervous system, Zfp106−/−mice undergo selectivemotor and sensory neuronal and axonal degeneration
speciﬁc to the spinal cord and peripheral nervous system. Neurodegeneration does not occur during development of Zfp106−/−
mice, suggesting that ZFP106 is likely required for the maintenance of mature peripheral motor and sensory neurons. Analysis
of embryonic Zfp106−/− motor neurons revealed deﬁcits in mitochondrial function, with an inhibition of Complex I within
the mitochondrial electron transport chain. Our results highlight a vital role for ZFP106 in sensory and motor neuron
maintenance and reveal a novel player in mitochondrial dysfunction and neurodegeneration.
†Equal contributors in alphabetical order.
Received: October 15, 2015. Revised: November 9, 2015. Accepted: November 11, 2015
© The Author 2015. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Human Molecular Genetics, 2016, Vol. 25, No. 2 291–307
doi: 10.1093/hmg/ddv471
Advance Access Publication Date: 24 November 2015
Original Article
291
Introduction
ZFP106 is a zinc ﬁnger protein with proposed roles in transcrip-
tional control, RNA metabolism, the immune response, muscle
development and differentiation and testes development (1–3).
Phosphorylation of ZFP106 increases following DNA damage,
whichmight suggest a possible role in the DNA damage response
pathway (4). Recently, ZFP106 has been identiﬁed as a novel fac-
tor regulating transcription initiation by targeting RNA-polymer-
ase I to the promoter of ribosomal RNA genes (5), linking for the
ﬁrst time ZFP106 function and RNA metabolism. Interestingly,
the human gene encoding ZFP106 (ZFN106) is located within a
familial amyotrophic lateral sclerosis (ALS) locus (ALS5) on
human chromosome 15, while human ZFP106 is proposed to lo-
calize to the nucleolus (1).
Zfp106 encodes a 1888-amino acid proteinwith twoN-terminal
C2H2 zinc ﬁnger motifs, two C-terminal CWCH2 zinc ﬁnger motifs
and seven WD40 repeats (2,3,6). Zinc ﬁnger motifs are important
for protein–protein interactions and nucleic-acid binding (7),
whilst WD40 repeats are involved in protein–protein interaction
and facilitate the formation of large multi-protein complexes (8).
Putative orthologues ofZfp106 are only found inmammals and ex-
hibit a high degree of conservation between species.
Zfp106 mRNA expression is proposed to be driven from two
promoters, with the resulting transcripts producing a number
of isoforms (2). Full-length ZFP106 (ZNF106) mRNA is expressed
ubiquitously and expression is particularly high in the heart,
skeletal muscle and testis (2). Nuclear respiratory factor-1 (NRF-1)
can activate Zfp106 mRNA expression, with expression patterns
of full-length Zfp106 and Nrf1 mRNA coinciding in mouse em-
bryos (2). A short isoform is speciﬁcally expressed in skeletal
muscle, regulated by myogenin, and is strongly upregulated dur-
ing myogenic differentiation (2).
While previous research on ZFP106 indicates different func-
tions, in this study we have created the ﬁrst ZFP106 animal
model to further understand its in vivo functions. We have
taken advantage of the resource provided by the international
Knock Out Mouse Project (KOMP) (9) and the Sanger Mouse Gen-
etics Project to further elucidate Zfp106 function. Mice homozy-
gous for the knockout ﬁrst promoter-less allele (tm1a(KOMP)
Wtsi) in Zfp106 develop severe gait and motor abnormalities
that deteriorate with age. The motor abnormalities exhibited by
Zfp106−/− mice are likely due to a severe progressive adult-onset
degenerative sensory-motor axonopathy.
Results
Zfp106 deﬁciency causes progressive motor
abnormalities
A knockout ﬁrst promoter-less allele (tm1a(KOMP)Wtsi) within
Zfp106was created by The Sanger Mouse Genetics Project (http://
www.sanger.ac.uk/mouseportal/) through KOMP (9). The con-
struct targets Zfp106 intron 1 on chromosome 2 and includes a
β-galactosidase (LacZ) reporter allele (see ‘Materials and Meth-
ods’). Mice homozygous for the tm1a(KOMP)Wtsi allele in
Zfp106 (Zfp106−/−) are born in Mendelian ratios (data not shown)
and both Zfp106−/−male and female mice develop an abnormal
gait from ∼3 weeks of age, which deteriorates with age, causing
animals to inaccurately place their limbs, especially their hin-
dlimbs, whenwalking across awire grate (Supplementary Mater-
ial, Movie S1). Zfp106−/− animals also become severely kyphotic
and develop limb grasping defects at 15-weeks of age whereby
they pull all of their limbs into their body (Fig. 1A and Supple-
mentary Material, Movie S1).
To assess Zfp106 expression we performed whole-genome
transcriptomic analysis (RNA-seq) on spinal cord and qPCR on
spinal cord and brain from adult wild-type (WT) mice and
Zfp106−/− littermates. The unbiased RNA-seq expression data
show that whilst some Zfp106 expression remains in spinal
cords of Zfp106−/− mice, the expression levels are <20% of those
identiﬁed in WT littermates (Table 1). qPCR of Zfp106 also re-
vealed reduced expression in Zfp106−/−mouse tissueswhen com-
pared with WT littermates; however, analysis via this technique
indicated lower Zfp106 expression in Zfp106−/− mice when com-
pared with RNA-seq analysis (0.4 and 0.7% of WT levels for
brain and spinal cord, respectively) (Fig. 1B). This reduction in
Zfp106 expression was also conﬁrmed via northern-blot analysis
from both brain and spinal cord (Supplementary Material, Fig.
S1). The muscle-speciﬁc transcript was also downregulated in
Zfp106−/− muscle via qPCR (Supplementary Material, Fig. S1).
We also conﬁrmed the expression pattern of Zfp106 using the
LacZ reporter contained within the Zfp106 knockout cassette,
with expression during embryogenesis and in many tissues in
adulthood, including the central nervous system (CNS) and
hind limb muscle (Supplementary Material, Fig. S1).
We evaluated the behavioural phenotypes of male (Supple-
mentary Material, Fig. S2) and female Zfp106−/− cohorts (Fig. 1)
and found no sex differences. Body weight of female Zfp106−/−
mice are signiﬁcantly reduced from 3 weeks of age compared
with WT and Zfp106+/− littermates (Fig. 1C; P = 0.04). When com-
paring grip strength of WT, Zfp106+/− and Zfp106−/− females we
found a dramatic reduction in Zfp106−/− mice at 6 and 13 weeks
of age (Fig. 1D). Rotarod testing revealed a similarly reduced
motor performance in Zfp106−/− females compared with WT lit-
termates (Fig. 1E). We also examined the behaviour of 6-week-
old WT, Zfp106+/− and Zfp106−/− littermates using a modiﬁed
SHIRPA analysis, which assesses a battery of simple phenotypic
traits, with an emphasis on neurological function (10,11). These
tests included: the presence/absence of tremors, limb grasping
of front or rear legs, gait, the ability to hang from a wire (wire
manoeuvre), and the ability to walk down a vertical wire grate
(negative geotaxis, see ‘Materials and Methods’). Table 2 sum-
marizes SHIRPA analysis from 6-week-old WT, Zfp106−/+ and
Zfp106−/− littermates. ∼66% Zfp106−/− mice display mild to mod-
erate tremors, >50% display limb grasping defects and all
Zfp106−/−mice are severely impaired in wire hanging and are un-
able to maintain grip when made to walk down a vertical wire
grate (negative geotaxis).
WT, Zfp106+/− and Zfp106−/− littermates were assessed in an
open ﬁeld paradigm, wherebymousemovement is trackedwithin
an arena for 30 min. We observed a progressive deterioration in
the distance moved (Fig. 1F), the mean velocity of movement
(Fig. 1G), and the percentage of time spent moving (data not
shown) between 7- and 14-week-old Zfp106−/−mice. To character-
ize these progressivemotor abnormalities furtherwe analysed the
number of placement errorsmade by either their front or rear legs
using the Locotronic® system (Fig. 1H). At 7 weeks of age Zfp106−/−
mice produce signiﬁcantly more front and rear leg errors com-
pared with WT littermates (front leg errors, WT 4.4 ± 1.4 versus
Zfp106−/− 16.6 ± 4.3, P < 0.05; rear leg errors, WT 4.2 ± 1.1 versus
Zfp106−/− 32.8 ± 5.2; P < 0.001). Importantly, the number of rear leg
errors signiﬁcantly increases in Zfp106−/−mice at 14 weeks of age
to 53.5 ± 6.4 (P = 0.045) compared with 7-week-old Zfp106−/−, show-
ing an age-dependent deterioration in motor coordination.
Zfp106+/−mice did not display any differences fromWT litter-
mates in any of the behavioural tests outlined above. Five one-
year old Zfp106+/− mice were also analysed by modiﬁed SHIRPA
with no obvious defects detected (data not shown).
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Zfp106−/− mice have a reduced lifespan
Lifespan of Zfp106−/− mice was determined as the time to reach
humane endpoint, deﬁned as the time taken to lose 20% of peak
body weight or an inability to right themselves within 20 s when
placed on their sides. Out of 17 Zfp−/−mice examined, the major-
ity were culled due to a 20% loss of peak body weight (n = 12),
whilst a smaller proportion were culled due to an inability to
right themselves impinging on their ability to feed (n = 5). All
Zfp106−/− mice exhibited severe locomotor deﬁcits at humane
endpoint. The average lifespan of female Zfp106−/− mice was
102 ± 5 days (n = 10) and for males was 107 ± 4 days (n = 7)
(Fig. 1I); there was no signiﬁcant difference in survival between
Zfp106−/− males and females (data not shown). WT and Zfp106+/−
littermates survived with no abnormalities up to 365 days.
Hind limb muscle physiology of early and late stage
Zfp106−/− mice
To further characterize the motor abnormalities in Zfp106−/−
mice, we analysed in vivo the physiological characteristics of
the fast twitch hind limbmuscles tibialis anterior (TA) and exten-
sor digitorum longus (EDL). Themaximum isometric force (tetan-
ic tension) was measured in the TA and EDL muscles from both
legs of 7- and 15-week-old WT, Zfp106+/− and Zfp106−/− litter-
mates (Fig. 2A–D). The maximum force generated from the TA
of 7-week-old Zfp106−/−mice was ∼65% less than WT littermates
and further reduced to∼75% ofWT littermates at 15-weeks of age
(Fig. 2A and B). Similarly, the tetanic tension of EDLmuscles from
7-week-old Zfp106−/− mice was ∼20% less than WT littermates
and reduced by ∼50% in 15-week-old Zfp106−/− mice compared
Figure 1. Behavioural analyses of Zfp106−/− mice reveal severe motor abnormalities. Black bars: Zfp106−/−, grey bars: Zfp106+/−, white bars: Zfp106−/−. (A) Photograph of
mutant Zfp106−/− mouse at 15-weeks of age displaying pronounced kyphosis and unable to coordinate hind limbs on wire grate. (B) qPCR analysis of Zfp106 expression
levels in brain and spinal cord of 6-week-old male WT and Zfp106−/− littermates (n = 3 per genotype); expression in Zfp106−/−mice is normalized to Zfp106 expression in
respectiveWT tissues, taken as a value of 1 (Log scale). (C) Femaleweights recordedweekly from ages 3 to 15weeks; at least ﬁvemicewere assessed per genotype per time
point. Weight is diminished in Zfp106−/− female mice from 3-weeks of age (P = 0.04) and continues to signiﬁcantly decrease, compared withWT and Zfp106+/− animals, to
15-weeks of age (P < 0.001). (D) Female grip strength and (E) accelerated Rotarod performance are reduced in Zfp106−/−mice at 6- and 13-weeks of age compared withWT
and Zfp106+/− littermates (n≥ 6 per genotype). (F and G) Open ﬁeld assessment of (F) distance moved, and (G) velocity for female mice at 7- and 14-weeks of age (see
‘Materials and Methods’). A reduction in distance moved (F), and velocity (G), was seen in 14-week-old female Zfp106−/− mice when compared with 7-week female
Zfp106−/− mice; P values are indicated (n ≥ 5 per genotype and time point) and 14-week old WT littermates. (H) Female mice assessed for defects in coordination of
front and rear legs at 7- and 14-weeks of age using the Locotronic® system (see ‘Materials and Methods’). Zfp106−/− mice made signiﬁcantly more front and rear leg
placement errors compared with WT littermates. Rear leg errors also signiﬁcantly increased for 14-week-old Zfp106−/− mice compared with 7-week-old Zfp106−/− mice
(n≥ 5 per time point and genotype; P value indicated). Numbers and percentages shown represent the mean ± SEM. *P < 0.05; **P < 0.001. (I) Survival of male and female
Zfp106−/− mice as determined by their humane endpoint (see ‘Materials and Methods’).
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with WT littermates (Fig. 2C and D). Thus, TA muscles are af-
fected earlier and more severely than the EDL muscles, as has
been previously reported inmousemodels of other neuromuscu-
lar disorders (12). Interestingly, both TA and EDL muscles dis-
played a clear deterioration in the amount of force generated as
Zfp106−/− mice aged.
We next determined the number of functional motor units
innervating EDL muscles in 7- and 15-week-old WT, Zfp106+/−
and Zfp106−/− mice (Fig. 2E and F). In 7-week-old Zfp106−/− mice,
therewas a small but signiﬁcant reduction inmotor unit survival,
such that 26 ± 0.9 motor units (n = 12) innervated the EDL in
Zfp106−/− mice compared with 31 ± 0.4 motor units (n = 10) in
WT littermates (P < 0.001). By 15 weeks, fewer motor units sur-
vived in Zfp106−/−mice, with 23 ± 1 motor units (n = 12) surviving
compared with 31 ± 0.5 motor units (n = 10) in WT littermates
(P < 0.001), suggesting a progressive loss of motor neurons.
Fast twitch muscles such as EDL normally fatigue rapidly and
cannotmaintain forcewhen repeatedly stimulated.We therefore
examined the fatigue characteristics of EDLmuscles in 7- and 15-
week-old Zfp106−/− mice, by undertaking a fatigue test in which
the muscles were repeatedly stimulated (Fig. 2G and H). Typical
fatigue traces from EDL muscles of WT and Zfp106−/− littermates
are depicted in Figure 2H showing that in Zfp106−/− mice there
was a clear shift in the fatigue pattern of EDL, becoming fatigue
resistant as the mice aged. From traces such as these, a fatigue
index (FI) was calculated for eachmuscle, where an FI of 1.0 indi-
cates that a muscle is completely fatigue resistant, as previously
described (13). Our ﬁndings revealed that 7-week-old WT mice
had a FI of 0.32 ± 0.04 (n = 10) (Fig. 2G and H) compared with
0.48 ± 0.06 in 7-week-old Zfp106−/− (n = 12), an increase of 33.3%,
although this differencewas not statistically signiﬁcant (P = 0.07).
However, by 15 weeks of age, the FI of EDL in Zfp106−/−mice was
0.69 ± 0.05 (n = 12), compared with 0.23 ± 0.02 (n = 10) in WT litter-
mates, a statistically signiﬁcant increase of 66.7% (P < 0.001), and
a statistically signiﬁcant increase of 30.4% over 7-week-old
Zfp106−/− mice (P = 0.019). These results show that in Zfp106−/−
mice, EDL muscles are signiﬁcantly more fatigue resistant than
those of WT littermates, a characteristic usually observed in
slow twitch muscles.
Zfp106 deﬁciency causes progressive motor neuron
degeneration with reactive gliosis and loss of motor and
sensory axons
Behavioural, physiological and histopathological studies of
Zfp106−/− mice all indicate possible neuronal defects. Therefore,
we examined the morphology of motor neurons and their
axons fromWT and Zfp106−/− littermates. Toluidine blue stained
semi-thin sections from the lumbar L4 and L5 ventral roots re-
vealed widespread loss of ﬁbres, active degeneration of motor
axons with no clear signs of regeneration and apparently normal
myelination (Fig. 3A and B). To assess motor neuron survival, we
counted the numberofmotor neurons from the sciatic pool in the
lumbar spinal cord (L3-L6) of 7- and 15-week-old WT, Zfp106+/−
and Zfp106−/− littermates (Fig. 3C and D). The number of motor
neurons of 7-week-old Zfp106−/− mice is reduced by ∼35% com-
pared with WT littermates and decreased by a further ∼15% at
15 weeks of age, corresponding to a total motor neuron loss of
50% in 15-week-old Zfp106−/− mice (Fig. 3C and D). Interestingly,
visualization of toluidine blue stained semi-thin sections of the
lumbar region of Zfp106−/− spinal cord showed the occasional
presence of vacuolated motor neurons, likely to be undergoing
cell death (Fig. 3E). Immunohistochemical staining of the lumbar
spinal cord of 15-week-old WT and Zfp106−/− littermates using
antibodies to GFAP (astrocytosis) and IBA-1 (microgliosis) also re-
vealed widespread reactive gliosis, coincidental with over 50%
motor neuron loss, not seen in WT or Zfp106+/− littermates
(Fig. 3F and G, and data not shown).
We performed p62 staining of spinal cord sections from
Zfp106−/−mice because p62 is commonly found localized into ag-
gregates in neurodegenerative disease (14). However, we did not
observe any altered localization or aggregation of p62 in the lum-
bar region of 15-week-old Zfp106−/− mice (data not shown). Ter-
minal deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) staining on ventral spinal cord of 15-week-old WT and
Zfp106−/− mice showed cells undergoing active cell death in
Zfp106−/− mice (Supplementary Material, Fig. S3A and B).
Given the striking loss of lowermotor neurons, we next exam-
ined the sensory system. Assessment of L4 and L5 dorsal roots
from 15-week-old female WT and Zfp106−/− littermates revealed
a loss of both large and small sensory axons (Fig. 4A and B). We
also observed degeneration of myelinated and unmyelinated
axons and no evidence of axonal regeneration or demyelination
(Fig. 4C). In addition, numerous L4 and L5 dorsal root ganglia
(DRG) of 15-week-old female Zfp106−/− mice were smaller
Table 1. Top 10 statistically signiﬁcant (adjusted P value <1E− 14)
positively and negatively regulated genes from Zfp106−/− spinal cords
via RNA-seq
Gene Fold difference
Calcoco2 0.15
Zfp106 0.19
Chodl 0.38
Calca 0.55
Pla2g3 0.60
Slc10a4 0.61
Mmp9 0.62
Aif1l 0.67
Dhcr24 0.69
Nefh 0.76
Mmp12 44.58
Cst7 19.97
Atp6v0d2 18.68
Cxcl10 13.25
Cxcl9 12.88
Itgax 12.23
Tgm1 11.89
Gpnmb 11.63
Lgals3 10.13
Igfbpl1 13.25
Table 2. Movement and neurological associated defects in Zfp106−/−
mice, assessed using modiﬁed SHIRPA analysis
Genotype Sample
sizea
Tremors
(%)b
Limb
grasp
(%)b
Wire
Manoeuvre
deﬁcits (%)b
Negative
geotaxis
deﬁcits
(%)b
WT 6 0 0 0 0
Zfp106+/− 7 0 0 0 0
Zfp106−/− 9 66.7 55.6 100 100
aFemale animals assessed at 6 weeks of age.
b% of animals that displayed defects in each of the semi-quantitative measures,
assessed during the modiﬁed SHIRPA test (see ‘Materials and Methods’).
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Figure 2.Assessment of hind limbmuscle force,motor unit survival andmuscle fatigue on femalemice. (A and B) Summaryof themaximum tetanicmuscle force generated
from the TA muscle. (A) TA tetanic muscle force generated by Zfp106−/−mice at 7-weeks of age (47 g ± 4 g) is reduced compared withWT littermates (133 g ± 4 g). TA tetanic
tension is further reduced in 15-week-old Zfp106−/−mice (32 g ± 4 g) compared with 7-week-old Zfp106−/−mice. (B) Representative traces of TA tetanic tension fromWT and
Zfp106−/−miceat 7- and 15-weeks of age. (C andD) Tetanicmuscle force generated fromthe EDLat 7- and15-weeksof age (see ‘Materials andMethods’). (C) EDL tetanicmuscle
force generated by Zfp106−/− mice at 7-weeks (29 g ± 1 g) is reduced compared with WT littermates (37 g ± 2 g) and becomes further reduced in 15-week-old Zfp106−/− mice
(21 g ± 3 g). (D) Representative traces of EDL tetanic tension fromWT, 7- and 15-week old Zfp106−/−mice. (E and F) The number of survivingmotor units in the EDLmuscle of
femalemice at 7- and 15-weeks of age;motor units are reduced in 7-week-oldZfp106−/−mice (26 ± 0.9) comparedwithWT littermates (31 ± 0.4), and are further reduced in 15-
week-oldZfp106−/−mice (23 ± 1). (F) Representativemotorunit traces fromEDLmuscles ofWT, 7- and 15-weekoldZfp106−/−mice. Each twitch trace recording is a singlemotor
unit. (G and H) FI (see ‘Materials and Methods’ section) of EDL muscle for female mice at 7 and 15-weeks of age. FI of 7-week old Zfp106−/− mice (0.48 ± 0.05) is increased
compared with WT littermates (0.32 ± 0.04) but not signiﬁcantly (P = 0.07). FI increases further in 15-week-old Zfp106−/− mice (0.69 ± 0.05) compared with 7-week old
Zfp106−/− mice. (H) Representative fatigue traces fromWT, 7- and 15-week Zfp106−/− mice, produced by repetitive stimulation of the EDL muscle for 180 s. Each line in the
trace represents a single tetanic tension. Results are presented as the mean ± SEM. At least 10 legs were assessed per genotype per time point. *P≤ 0.001, or indicated
within each chart when comparing Zfp106−/− mice from 7- and 15-weeks of age.
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Figure 3.Motor neuron and axonal degeneration and gliosis in Zfp106−/−mouse spinal cord. (A and B) Representative toluidine blue stained sections of lumbar L4 and L5
ventral roots from 15-week old WT (A) and Zfp106−/− (B) mice. Zfp106−/−mice have fewer motor axons than WT littermates (spaces are marked with asterisks), and have
degenerating axons, indicatedwith arrow head. Scale bar is 20 μm. (C) Representative images of the ventral horn of lumbar spinal cord sections stained for Nissl fromWT,
7- and 15-week-old Zfp106−/−mice. The number ofmotor neurons in the sciatic pool (inset) was counted for each genotype and age to calculatemotor neuron survival (D).
Scale bars: main images 200 μm inset 100 μm. (D) The survival of motor neurons in the sciatic pool in female mice at 7- and 15-weeks of age. Motor neuron survival in
7-week-old Zfp106−/− mice (294 ± 11) is reduced compared with WT littermates (481 ± 9) and further reduced in 15-week-old Zfp106−/− mice (217 ± 9). Numbers
represent the mean ± SEM. At least ﬁve animals were assessed per genotype per time point (*P < 0.001). (E) Representative toluidine blue stained section of 15-week-old
Zfp106−/− lumbar spinal cord showing an example of a vacuolated (arrow) motor neuron. (F and G) Lumbar spinal cord sections of 15-week-old WT (F) and Zfp106−/−
(G) mice stained for IBA-1 (green), GFAP (red) and Nissl (blue). Immunoreactivity for micro- and astrogliosis is dramatically increased in the lumbar of 15-week-old
Zfp106−/− mice compared with WT littermates. Scale bar is 20 μm.
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compared with WT littermates, some showing signs of chroma-
tolysis (Fig. 4D and E). Examination of dorsal fasciculi in the
spinal cord revealed degeneration of ascending sensory axons
(Fig. 4F and G). However, we did not observe any morphological
or pathological defects in the descending spinal cord tracts
(data not shown). Thus, Zfp106−/− mice have deﬁcits in both the
motor and sensory neuronal systems of the spinal cord.
Zfp106−/− neuronal loss is not developmental
Following the identiﬁcation of progressive neurodegeneration in
both motor and sensory neurons of the spinal cord, we next
sought to establish whether neuronal abnormalities are present
during development. Motor neuron survival was unaffected in P9
Zfp106−/− mice compared with WT littermates (Fig. 5A–C) and
DRG from Zfp106−/−micewere also indistinguishable fromWT lit-
termates at this age (data not shown). Axonal morphology was
quantiﬁed on toluidine blue stained semi-thin sections from
the lumbar L4 and L5 ventral and dorsal roots, and from sciatic
nerve sections of P9 animals (Fig. 5D–L and Supplementary Ma-
terial, Fig. S4). Axonal morphology from ventral roots was similar
between WT controls and Zfp106−/− mice (Fig. 5D–F). However,
therewas a signiﬁcant reduction in axonal diameter on the sciat-
ic nerve of Zfp106−/−micewhen compared toWT controls (Fig. 5J–
L and SupplementaryMaterial, Fig. S4). This is accompaniedwith
a signiﬁcant shift in the frequency distribution towards a thinner
axon diameter and an increased g-ratio in Zfp106−/− dorsal roots
when compared with WT (Fig. 5G–I). Thus, deﬁciency of Zfp106
leads to mild early changes in axonal morphology but does not
cause neuronal loss at P9.
Figure 4.Axonal degeneration of sensoryneurons. (A, B) Representative toluidine blue stained sections of lumbar L4 and L5 dorsal roots fromWT (A) and Zfp106−/− (B)mice.
Zfp106−/−mice have fewer sensory axons, and degenerating axons, indicated with arrowhead. Scale bar is 20 μm. (C) Electronmicrograph of Zfp106−/− dorsal root showing
degenerating myelinated axons (arrow head) and evidence of loss of unmyelinated axons with denervated Schwann cells (arrow). Scale bar is 5 μm. (D and E)
Representative toluidine blue stained section of lumbar DRG from WT (D) and Zfp106−/− (E) mice. Numerous DRG neurons from Zfp106−/− mice (E) are shrunken and
irregular and some show signs of chromatolysis, with ﬂattened nuclei (indicated with arrows). Scale bar is 20 μm. (F and G) Representative toluidine blue stained
sections of the dorsal fasciculi from the lumbar spinal cord from WT (F) and Zfp106−/− (G) mice showing fewer axons and axonal degeneration (arrow heads). Scale bar
is 20 μm. All images are of 15-week-old WT or Zfp106−/− mice, images representative of three animals per genotype.
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Zfp106 deﬁciency does not cause major abnormalities
in the brain
Weperformed an immunohistological examination on the brains
of female 15-week-old WT and Zfp106−/− littermates using the
following stains and proteinmarkers: H&E, GFAP, IBA-1, p62, ubi-
quitin, myelin basic protein and neuroﬁlament. There were no
major abnormalities in the anatomy of the brain or differences
in reactive gliosis, p62, MBP or neuroﬁlament staining between
WT and Zfp106−/− mice (data not shown). Therefore, deﬁciency
in Zfp106 causes speciﬁc defects in the spinal cord and PNS but
not the brain, despite being expressed at similar levels in the
brain (Fig. 1B).
Muscle histopathology in Zfp106−/− mice
The changes in the physiological characteristics of the TA and EDL
muscles of Zfp106−/−mice led us to perform amore in-depthmus-
cle histopathological analysis. Examination of gross morphology
of Zfp106−/−mice clearly showed a reduced mass and diminished
size of muscles (Supplementary Material, Fig. S5A). Analysis of 6-
and 14-week-old WT and Zfp106−/− littermates revealed reduced
Figure 5.Neuronal survival and axonalmorphology at P9. (A and B) Representative images of the ventral horn of lumbar spinal cord sections stained for Nissl fromP9WT
and Zfp106−/−mice. The number of motor neurons in the sciatic pool (inset) was counted for each genotype. Scale bars: main images 200 μm, inset 100 μm. (C) Survival of
motor neurons in the sciatic pool in female mice at P9. Motor neuron survival is unaffected in P9 Zfp106−/− mice (530 ± 15) compared with WT littermates (508 ± 23).
Numbers represent the mean ± SEM. At least ﬁve animals were assessed per genotype per time point. (D and E) Representative toluidine blue stained sections of
lumbar L4 and L5 ventral roots from P9 WT (D) and Zfp106−/− (E) mice. (F) Distribution graph relating g-ratio to axon diameter of all myelinated axons analysed from
ventral roots show no differences between WT and Zfp106−/−. Scale bar is 20 μm. (G and H) Representative toluidine blue stained sections of lumbar L4 and L5 dorsal
roots from P9 WT (G) and Zfp106−/− (H) mice. Scale bar is 20 μm. (I) Distribution graph relating g-ratio to axon diameter from dorsal roots. Zfp106−/− mice have a
signiﬁcant shift in the frequency distribution towards a thinner axon diameter and an increased g-ratio compared with WT (P < 0.001). (J and K) Representative
toluidine blue stained sections of the sciatic nerve from P9 WT (J) and Zfp106−/− (K) mice. Scale bar is 10 μm. (L) Distribution graph relating g-ratio to axon diameter for
the sciatic nerve. Zfp106−/− mice show a signiﬁcant shift in the frequency distribution towards a smaller axon diameter compared with WT animals (P < 0.001) but no
change in g-ratio.
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TA, gastrocnemius and soleus muscle weight in 14-week but not
6-week-old Zfp106−/− mice when compared with WT littermates
(P < 0.01). However, no differences were found in EDL muscle
weights at either 6 or 14 weeks of age (Fig. 6A and data not
shown) or in tibia length from 14-week old WT and Zfp106−/−
littermates (Supplementary Material, Fig. S5B). Histopathological
analysis of muscles (gastrocnemius, soleus and EDL) from
6-week-old Zfp106−/− littermates was comparable to that seen in
WT littermates (data not shown). However, Haematoxylin and
eosin (H&E) staining of the gastrocnemius from 14-week-old
Zfp106−/− mice, which had atrophied by ∼80% at that stage,
revealed extensive muscle ﬁbre atrophy, with areas of increased
nuclearity, and evidence of reorganization and ﬁbre regeneration
(Fig. 6B and C). Extensive areas of the gastrocnemius were also
ﬁbrotic (Fig. 6D and E). We also assessed the distribution of
ﬁbre types within the gastrocnemius and soleus using NADH–
tetrazolium reductase (NADH-TR) and ATPase stainings and
found increased type I/highly oxidative ﬁbres in the gastrocne-
mius and soleus of 14-week-old Zfp106−/− mice compared with
WT littermates (Fig. 6F –I). Moreover, in all sections of soleus
muscle from Zfp106−/−mice examined therewas a greater spread
of ﬁbre size, ranging from very small to very large muscle ﬁbres,
compared with WT soleus muscle (Supplementary Material,
Fig. S5C). In addition, the soleus of 14-week-old Zfp106−/− mice
had fewer ﬁbres when compared with WT littermates (Fig. 3J).
Thus, Zfp106 deﬁciency causes progressive muscle pathology.
Zfp106 deﬁciency affects genome-wide transcription
A role in transcriptional control has been recently proposed for
ZFP106 (5). To assess how Zfp106 deﬁciency might affect tran-
scriptional regulation, we analysed genome-wide transcriptional
changes from the spinal cords of 6-week-old Zfp106−/−mice using
RNA-seq. At this stage, Zfp106−/−mice already display motor and
sensory neuron pathology (Figs 3 and 4). Analysis of gene expres-
sion revealed a large number of differentially expressed genes,
the majority of which were upregulated in Zfp106−/− when com-
pared with WT littermate spinal cords (Table 1 and Supplemen-
tary Material, Fig. S6A). Pathway analysis of differentially
expressed genes showed a variety of affected cellular processes,
prominently including the inﬂammatory response, metabolic
disease, cell-to-cell signalling and interaction, hematological
system function, immune cell trafﬁcking and cell motility.
Zfp106 deﬁciency causes mitochondrial abnormalities
To investigate whether mitochondrial dysfunction may be a fea-
ture of Zfp106−/− neurons, we examined the mitochondrial prop-
erties of embryonic motor neurons derived from WT, Zfp106+/−
and Zfp106−/− littermates.
We ﬁrst assessed mitochondrial membrane potential (Δψm),
an indicator of the mitochondrial energetic state, measured
using tetramethylrhodamine methylester (TMRM), a cell-perme-
able, potentiometric, ﬂuorescent dye that is readily sequestered
byactivemitochondria (15,16). TMRM is a positively chargedmol-
eculewhich accumulateswithinmitochondria in inverse propor-
tion to Δψm; hyperpolarized mitochondria will accumulate more
dye, and hypopolarized mitochondria will accumulate less dye.
Fluorescent dye accumulation in mitochondria is then optically
detected by confocal microscopy. We found that mitochondria
in motor neurons derived from Zfp106−/− mice were associated
with a signiﬁcant increase (27% ± 7%, P < 0.001) in the TMRM sig-
nal comparedwithmitochondria fromWTmotor neurons (n = 34
cells) (Fig. 7A). In Zfp106+/− motor neurons, values of TMRM
Figure 6.Muscle histology of WT and Zfp106−/−male mice. (A) Muscle weights for
the TA (WT, 62 mg ± 1 mg; Zfp106−/−, 34 mg ± 1 mg), EDL (WT, 11 mg ± 0.4 mg;
Zfp106−/−, 11 mg ± 0.4 mg), gastrocnemius (WT, 155 mg ± 1 mg; Zfp106−/−,
29 mg ± 23 mg) and soleus (WT, 11 mg ± 0.2 mg; Zfp106−/−, 5 mg ± 0.3 mg) from
male 14-week old WT and Zfp106−/− littermates (n = 3). TA, gastrocnemius and
soleus weights are signiﬁcantly different from WTs (*P < 0.01). (B–I)
Representative images of muscle histopathology from 14-week-old WT and
Zfp106−/− mice: (B and C) H&E staining of the gastrocnemius shows signiﬁcant
atrophy, reduced ﬁbre size and centralized nuclei (yellow arrows) in Zfp106−/−
muscle compared with WT littermates; (D and E) Masson’s trichome staining of
gastrocnemius muscle reveals ﬁbrosis in Zfp106−/− muscle (E), evident with
increased blue staining; (F and G) NADH-TR staining of the gastrocnemius
shows greatly increased dark blue staining in Zfp106−/− muscle (G) compared
with WT littermates, indicative of a higher proportion of slower twitch, type I
muscle ﬁbres; (H and I) ATPase staining of Zfp106−/− soleus muscle (I) showing
an increase in darkly stained ﬁbres, indicating an increase in the proportion of
type I ﬁbres overall. Scale bars: main images 20 μm, inset 10 μm. (J) Type I (WT,
253 ± 6 ﬁbres; Zfp106−/−, 147 ± 10 ﬁbres), type IIa (WT, 579 ± 95 ﬁbres; Zfp106−/−,
141 ± 40 ﬁbres) and total ﬁbre number (WT, 833 ± 92 ﬁbres; Zfp106−/−, 261 ± 38
ﬁbres) were counted for the soleus muscle from 14-week-old WT and Zfp106−/−
littermates using ATPase staining. The soleus from Zfp106−/− mice has
signiﬁcantly fewer muscle ﬁbres than that of WT mice (P < 0.01).
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ﬂuorescence were not signiﬁcantly different from WT (Fig. 7A).
These data suggest that Zfp106 deﬁciency is associated with in-
creased basal Δψm in embryonic motor neurons, at least in vitro.
We next investigated how Zfp106 deﬁciency results in an in-
crease in Δψm in embryonic motor neurons from Zfp106
−/− mice
when compared with Zfp106+/− and WT littermates. In cells
with normal oxidative phosphorylation, Δψm is maintained by
the proton pumpactivity of the respiratory chain. However, if oxi-
dative phosphorylation is impaired, then hydrolysis of ATP by the
F1FO-ATP synthase (Complex V) can pump protons across the
inner membrane and so maintain Δψm (17). Application of
the inhibitor of the F1FO-ATP synthase, oligomycin, to WT
motor neurons increased Δψm by 3 ± 0.1% (n = 23) (Fig. 7B), and
in Zfp106+/− motor neurons by 5 ± 0.3% (n = 27). However, expos-
ure of Zfp106−/−motor neurons to oligomycin caused a profound
decrease in Δψm (TMRM signal fell by 17% ± 3%, P < 0.001, n = 32)
(Fig. 7B). Thus, in Zfp106−/−motor neurons, the impaired activity
of the respiratory chain switches the F1FO complex to anATP con-
sumption mode which serves to maintain Δψm.
The redox state of NADH or FAD is a function of respiratory
chain activity and the rate of substrate supply. We measured
the resting level of NADH and FAD++ autoﬂuorescence and gener-
ated the ‘redox index’; a ratio of the maximally oxidized (re-
sponse to FCCP) and maximally reduced (response to sodium
cyanide (NaCN)) signals. The redox index of NADH in Zfp106−/−
motor neuronswas signiﬁcantlymore oxidized than inWT litter-
mates (WT: 39% ± 3%, n = 35 versus Zfp106−/−: 58% ± 4%, n = 46;
P < 0.001) (Fig. 7C andD).We also estimated the levels of themito-
chondrial pool of NADH, the substrate for complex I. NADH levels
were signiﬁcantly increased in Zfp106−/− motor neurons (Fig. 7E)
Figure 7.Mitochondrial abnormalities in Zfp106−/− embryonic motor neurons. (A) Resting Δψm from embryonic WT, Zfp106
+/− and Zfp106−/−motor neurons, estimated by
live cell imaging using TMRM. Data are normalized to resting Δψm forWT (100%) and represent themean ± SEM. (B) Representative traces of Δψm (TMRM, arbitrary units) in
response to oligomycin (2 μg/ml) (inhibitor of the F1FO-ATP synthase), rotenone (5 μ) (inhibitor of complex I) and the minimum TMRM ﬂuorescence achieved after
addition of FCCP 1 μ (uncoupling agent) for WT and Zfp106−/− embryonic motor neurons. Following oligomycin addition WT motor neuron Δψm hyperpolarises,
whilst Zfp106−/− depolarises. (C) NADH autoﬂuorescence monitored in WT and Zfp106−/− motor neurons, the addition of FCCP maximizes mitochondrial respiration,
thus minimizes mitochondrial NADH. NaCN was added to block mitochondrial respiration and therefore maximize mitochondrial NADH. Redox index (the initial
redox level expressed as a percentage of the range) and mitochondrial NADH level (the difference in absolute values between the minimum and maximum NADH
autoﬂuorescence) are described graphically. (D) NADH redox index for WT, Zfp106+/− and Zfp106−/− motor neurons calculated from (C). NADH redox index is increased
in Zfp106−/− embryonic motor neurons (58% ± 4%) compared with WT littermates (39% ± 3%). (E) Mitochondrial pool of NADH represented as % of WT. NADH levels are
increased in Zfp106−/− (138% ± 9.1%) motor neurons when compared with WT. (F) FAD autoﬂuorescence monitored in WT and Zfp106−/− motor neurons, the addition of
FCCPmaximizes respiration, increasing FAD autoﬂuorescence to maximal levels, whilst NaCN inhibits respiration, reducing FAD autoﬂuorescence to minimal levels. (G)
FAD redox index forWT, Zfp106+/− and Zfp106−/−motor neurons, calculated by normalizing the FCCP response to 100% and the NaCN response to 0%. FADH redox index is
increased in Zfp106−/− embryonic motor neurons (89% ± 6%) compared with WT littermates (49% ± 3%). (H) Mitochondrial pool of FAD represented as % of WT. FAD levels
are decreased in Zfp106−/−motor neurons (45.6% ± 5.2%)when comparedwithWT. Data from (A–H) are represented asmean ± SEM; n≥ 34motor neurons per genotype, per
condition. *P < 0.05; **P < 0.01.
300 | Human Molecular Genetics, 2016, Vol. 25, No. 2
when compared with WT controls. Thus, the combination of ac-
cumulating substrate and a diminished redox index in Zfp106−/−
motor neurons suggest that Zfp106 deﬁciency leads to functional
inhibition of the NADH-dependent (Complex I) mitochondrial
respiration.
In addition, FAD++ levels were increased in Zfp106−/− motor
neurons compared with WT littermates (WT: 49% ± 3% versus
Zfp106−/− 89% ± 6%; n = 47; P < 0.001) (Fig. 7F and G). The levels of
the mitochondrial pool of FAD were also estimated; FAD levels
were signiﬁcantly lower in Zfp106−/− motor neurons when com-
pared with WT controls (Fig. 7H). These ﬁndings suggest that
Zfp106 deﬁciency results in activation of Complex II respiration.
The FAD redox state in WT motor neurons (n = 37) was indistin-
guishable from Zfp106+/− motor neurons (n = 44) (Fig. 7F and G).
Thus, the striking abnormalities in motor neuron mitochondrial
properties may underlie the neurodegenerative effects caused by
Zfp106 deﬁciency.
Discussion
Zfp106 is expressed during development and ubiquitously in
adulthood, however, its functions remain unknown. Here, we re-
port a new Zfp106-deﬁcient mouse strain, which presents with
reduced body weight from 3 weeks of age, a reduction in grip
strength, the appearance of progressive gait abnormalities and
the development of a severe kyphosis compared with WT and
Zfp106+/− littermates (Fig. 1 and Supplementary Material, Movie
S1). These phenotypes were associated with neuromuscular def-
icits. Physiological and histopathological analyses revealed that
Zfp106−/− mice undergo a progressive loss of motor neurons, de-
generation of motor and sensory axons together with progres-
sive, severe muscle atrophy (Figs 2, 3, 4 and 6). Importantly, we
established that neurodegeneration is progressive and does not
occur during development, as motor and sensory neurons were
intact at P9. However, mild changes in axonal morphology were
present at this early stage (Fig. 5), suggesting that the neurode-
generation process may be already starting.
Interestingly, despite Zfp106 being expressed throughout the
CNS (2), abnormalities in Zfp106−/− mice are conﬁned to lower
motor neurons, sensory neurons and their peripheral axons,
and in the dorsal spinal cord ascending tracts (Figs 3 and 4). No-
major morphological or pathological abnormalities were ob-
served in the descending spinal cord tracts or in other brain
regions such as cerebellum, basal ganglia, thalamus, hippocam-
pus or cortex. Thus, preservation of Zfp106 expression levels is es-
sential for the maintenance and survival of spinal cord residing
neurons and their axons, suggesting that spinal cord residing
neurons, with their exceptionally long axons, are particularly
susceptible to changes in Zfp106 expression. It may be possible
that neurons from other brain areas may also be compromised,
but the rapid degeneration of spinal cord neurons may preclude
pathology potentially appearing in other areas. Future studies
conditionally deleting Zfp106 speciﬁcally in different brain
areas will be required to address this issue.
Histopathological assessment of young (6-week-old) Zfp106−/−
muscle did not reveal overt pathological abnormalities (data not
shown), whilst 14-week-old Zfp106−/− mice display varying de-
grees of muscle involvement ranging from no signiﬁcant atrophy
in the EDL to an ∼80% weight loss of the gastrocnemius (Fig. 6).
This suggests that the observed muscle pathology may be sec-
ondary to the neuronal degeneration. However, it is possible
that deﬁciency of Zfp106 in muscle also contributes to the neuro-
degeneration, and future studies that conditionally remove
Zfp106 from neurons or muscle will clarify this point.
In humans, ZFP106 is localized to the nucleus, and with the
presence of N- and C-terminal zinc ﬁngermotifs, is likely to regu-
late gene expression (1). Although several commercial antibodies
are available against human ZFP106, none of them recognize en-
dogenousmouse ZFP106, at least frombrain and spinal cord (data
not shown). Thus, we used RNA-seq analysis to gain insight into
the functional consequences of Zfp106 deﬁciency, showing a
number of genes misregulated due to Zfp106 deﬁciency. Pathway
analysis of the differentially regulated genes supports a role for
Zfp106 in neuronal maintenance and survival. Previous research
has shown that NRF-1, a transcription factor linked to the regula-
tion of mitochondrial function (18) and neurite outgrowth (19), is
important in the transcription of full length ZFP106 (2). Nrf1 null
mice are embryonic lethal, however, mice in which Nrf1 is spe-
ciﬁcally deleted from the CNS (CNS conditional Nrf1−/− mice)
develop a juvenile aggressive neurodegenerative phenotype
(20,21). Neurodegeneration is more widespread in CNS con-
ditional Nrf1−/− mice compared with Zfp106−/− mice, involving
alterations in the hippocampus and cerebellum but, importantly,
CNS conditional Nrf1−/− mice display pathology in the ventral
horn of the spinal cord, including increased oxidative stress.
Whether Zfp106 plays a role in the development of the Nrf1−/−
conditional knock out phenotype remains uncertain, however,
the effect of Nrf1−/− on spinal cord neuronal morphology has
similarities to the abnormalities observed here in Zfp106−/−
mice. The contribution of ZFP106 to neuronal survival within
the spinal cord and PNS may suggest a speciﬁc role as a down-
stream regulator of NRF-1.
Mitochondrial dysfunction has been proposed to be an insti-
gating factor in many neurodegenerative conditions (22). We
showhere that a deﬁciency in Zfp106 causes profoundmitochon-
drial abnormalities in embryonic motor neurons (Fig. 7). Deﬁ-
ciency of Zfp106 induces inhibition of Complex I within the
electron transport chain of mitochondria and activation of Com-
plex II. It has been previously shown that Complex II can become
activated in order to compensate for Complex I inhibition, lead-
ing to the hydrolysis of ATP by the F1FO-ATP synthase (Complex
V) and the pumping of protons across the inner mitochondrial
membrane (23,24). Overall, these abnormalities result in an in-
crease in Δψm, as observed in Zfp106
−/− embryonic motor neu-
rons. Interestingly, elevated Δψm can lead to an increase in the
production of reactive oxygen species (ROS) and can be a cause
of neuronal cell death (25,26). Furthermore, inhibition of Complex
I and the resulting activation of Complex II have been shown to
reverse the ﬂow of electrons within the electron transport
chain and produce free radicals (27), which can in turn lead to
mitochondrial and cellular damage. Although we provide strong
evidence of mitochondrial dysfunction due to Zfp106 deﬁciency,
whether this dysfunction is directly or indirectly mediated by
ZFP106 remains an open question.
Mitochondrial abnormalities have been reported in a variety
of neurodegenerative disorders affectingmotor and sensory neu-
rons in the spinal cord and their axons, including motor neuron
diseases such ALS (28–30), spinal muscular atrophy (SMA) (31)
and prominently in peripheral neuropathies, including Charcot-
Marie-Tooth (CMT) (32). A number of causative CMT genes are as-
sociatedwithmitochondrial function, including:MFN2,GDAP1 or
MT-ATP6 (33–35) and the Δψmof CMTpatients carryingmutations
in MFN2 or GDAP1 is disrupted (36,37). Furthermore, peripheral
neuropathy is observed in patients with mitochondrial diseases,
such as Leigh’s disease, mitochondrial neurogastrointestinal en-
cephalopathy (MNGIE), neuropathy, ataxia and retinitis pigment-
osa (NARP) (38) and spastic paraplegia with optic atrophy and
neuropathy (SPG55) (39).
Human Molecular Genetics, 2016, Vol. 25, No. 2 | 301
Any possible role for ZFP106 in human disease remains to be
established, as disease-causingmutations in ZFN106have not yet
been identiﬁed. The neuro-anatomical phenotypes observed in
Zfp106−/−mice have striking similarities with human axonal sen-
sory-motor neuropathies, such as CMT type 2 (CMT2). CMT2
prevalently affect the sensory and motor nerves, but also show
loss ofMNs, spinal cord gliosis and degeneration of the fasciculus
gracilis, as documented here for Zfp106−/−mice. Recessive forms
of CMT2 usually have an earlier onset, occurring in the ﬁrst dec-
ade of life and frequently before the age of two (40,41). These
characteristics are similar to the deﬁcits observed in Zfp106−/−
mice, which start developing symptoms at weaning (Fig. 1 and
Supplementary Material, Movie S1). However, since the function
of humanZFP106 is not yet clear, it will be important to screen for
ZFN106mutations in early-onset CMT2 cases (42), but alsomilder
forms of CMT, as well as other neurodegenerative disease in
which there is degeneration of either motor or sensory neurons,
such as ALS and progressive muscular atrophy (PMA).
ZFN106 is located onhuman chromosome15within the critical
region of a previously mapped familial juvenile ALS linked region
(ALS5) (43). Although a recent report suggests that mutations in
Spatacsin (SPG11) are causative of ALS5, it is not clear if SPG11mu-
tations explain all availableALS5-linked kindreds (43–45). Interest-
ingly, a recent report identiﬁed ZFP106 as a novel factor regulating
the initiation of transcription by targeting RNA-polymerase I to
the promoter region of ribosomal RNA genes (5). This, together
with ZFP106 proposed localization to the nucleolus links ZFP106
functionwith nucleolus function and RNAmetabolism abnormal-
ities, which together with mitochondrial dysfunction, are three
proposed common pathomechanisms leading to ALS (46,47).
In conclusion, our ﬁndings indicate that Zfp106 deﬁciency im-
pairs mitochondrial function and is required for the mainten-
ance and survival of speciﬁc motor and sensory neurons in vivo.
Although no ZFN106 mutations have yet been found in human
disease, the phenotype of Zfp106−/− mice, comprising spinal
cord speciﬁc neuronal deﬁcits and mitochondrial dysfunction,
raises the intriguing and novel possibility that ZFP106 is involved
in neurodegenerative disease.
Materials and Methods
Mice
Zfp106−/− mice (Zfp106tm1a(KOMP)Wtsi) were generated through the
KnockoutMouseProject (KOMP),whichaims toproduceembryonic
stem cellswith knockouts in a numberofmouse genes all ofwhich
will be publically available (http://www.komp.org/geneinfo.php?
geneid=87357). The Zfp106−/− mice were generated by targeting
C57BL/6N ES cells using a knockout ﬁrst, promoter-less allele
(tm1a(KOMP)Wtsi) (http://www.komp.org/alleles.php#conditional-
promoterless-csd). The construct targeted Zfp106 intron 1, inserting
a Neomycin resistance and a LacZ reporter cassette ﬂanked by ﬂip-
pase recombinase (Flp) target sites (FRT). LoxP sites were also engi-
neered ﬂanking Zfp106 exon 2, allowing for the conversion to a
conditional allele via Flp recombination, followed by crossing to ap-
propriate Cre lines. We conﬁrmed the location of the tm1a(KOMP)
Wtsi allele in the Zfp106 geneofZfp106−/−miceusing Southern blot-
ting (data not shown).
WT, Zfp106+/− and Zfp106−/− mice were on a hybrid C57BL/
6NTac/Den;C57BL/6J-Tyrc-Brd;C57BL/6N background and as-
sessed as littermates. Experiments were performed blind to
genotype and the humane endpoint was deﬁned as a loss of
20% body weight or an inability to right after 20 s. Animals were
assessed daily and weighed weekly.
Behavioural analysis
WT, Zfp106+/− and Zfp106−/− littermate female only mice were as-
sessed for grip strength (BioSeb, Chaville, France) of all four
limbs, as per themanufacturer’s instructions. Grip strength read-
ings were taken twice each at 6- and 13-weeks of age and the
mean of both values for each time point per animalwas used. Co-
hort sizes per time point were as follows: 6-weeks: 16 WT, 16
Zfp106+/− and 14 Zfp106−/− animals; 13-weeks: 13 WT, 9 Zfp106+/−
and 7 Zfp106−/− animals.
WT, Zfp106+/− and Zfp106−/− littermate female mice were
placed on an accelerating rotarod (Ugo Basile) twice a day, three
times a week, at 6- and 12-week time points, as described previ-
ously (48). Cohort sizes per time point were as follows: 7-weeks: 6
WT, 10 Zfp106+/− and 14 Zfp106−/− animals; 12-weeks: 7 WT, 8
Zfp106+/− and 8 Zfp106−/− animals.
Modiﬁed SHIRPAmethodswere performed as described previ-
ously (10,11). Tremors were qualitatively assessed by observation
in aviewing jar and recorded as having tremors (1) or not (0). Limb
grasping was assessed as either clasping one or more limbs (1) or
not (0). The wire manoeuvre was assessed by hanging animals
from a wire by their forelimbs and recording the degree to
which they were able to hold their body weight. Animals were
only scored as defective if they could not hang onto the wire for
more than 1 s. Negative geotaxis involves animals walking down
a vertical grate. Animals that slipped down at least half of the
wire gratewere scored as defective. Micewere subject tomodiﬁed
SHIRPA analysis at 6-weeks of age and included: 15 WT, 15
Zfp106+/− and 17 Zfp106−/− animals.
WT, Zfp106+/− and Zfp106−/− littermate female mice were
monitored in an open ﬁeld paradigm (Noldus Ethovision 3.1). An-
imals were placed in an arena and monitored using Ethovision
3.1 tracking software for 30 min at 7- and 14-week time points.
The parameters distance moved (cm) and velocity (cm/s) were
averaged per genotype and time point. Cohort sizes per time
point were as follows: 7 weeks: 15 WT, 13 Zfp106+/− and 14
Zfp106−/− animals; and 14 weeks: 5 WT, 9 Zfp106+/− and 6
Zfp106−/− animals.
WT, Zfp106+/− and Zfp106−/− littermate female mice accuracy
of paw placement was analysed using Locotronic® (Intelli-Bio,
France). Brieﬂy, animals begin in a starting area, illuminated
withwhite light andmove downacorridor consisting of aﬂat lad-
der (bars: 3 mm diameter, spaced by 7 mm) with three infrared
sensors above and below each bar space, which registered move-
ment errors 100 times a second. Animals were assessed three
times each at 7- and 14-weeks of age; averages were taken per
animal and at each time point. Cohort sizes per time point
were as follows: 7 weeks: 10WT, 12 Zfp106+/− and 14 Zfp106−/− an-
imals; and 14 weeks: 6 WT, 7 Zfp106+/− and 5 Zfp106−/− animals.
Physiological assessment of hindlimb muscle force,
motor units and FI
Muscle force, motor unit number and FI for female WT, Zfp106+/−
and Zfp106−/− littermates were examined at 7- and 15-weeks of
age, as described previously (49). Cohort sizes per time point
were as follows: 7 weeks: 5 WT, 6 Zfp106+/− and 6 Zfp106−/− ani-
mals; and 15 weeks: 5 WT, 5 Zfp106+/− and 6 Zfp106−/− animals.
Brieﬂy, mice were anesthetized (4.5% chlorohydrate, 1 ml/100 g
of body weight), the distal tendons of the TA and EDL muscles
in both hindlimbs attached to isometric force transducers (Dyna-
mometer UFI Devices, Welwyn Garden City, UK), and the sciatic
nerve exposed and sectioned. Isometric contractions were eli-
cited by stimulating the nerve to the TA or EDL using squarewave
pulses of 0.02 ms duration at supra-maximal intensity, via silver
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wire electrodes. Contractions were elicited by trains of stimuli at
frequencies of 40, 80 and 100 Hz and measured using Scope soft-
ware. The number of motor units innervating the EDL was deter-
mined by stimulating the motor nerve with stimuli increasing
intensity, resulting in incremental increases in twitch tension
due to successive recruitment of motor axons. The number of in-
crements was counted giving an estimate of the number of func-
tional motor units present in EDL muscle. The FI for the EDL
muscle was examined by stimulating the EDL at 40 Hz for 250 ms
every second for 180 s. Contractions were recorded with a pen re-
corder (LectromedMultitrace 2) and the FI calculated as ameasure
of muscle fatigability and expressed as a ratio: FI = Ft180/Ft0.
Morphological assessment ofmuscle andneuronal tissue
Ten micrometer cross-sections of frozen gastrocnemius, soleus
and EDL were examined with H&E, Masson’s trichrome and
NADH-TR activity to determine the oxidative capacity of the
muscle ﬁbres, as described previously (50). Then, 10 μm cross-
sections of the soleus were subjected to ATPase staining (acid
preincubation at pH 4.47) (51) and the total number of ﬁbres
and proportion of ﬁbre types within the soleus were assessed
(52). Musclemorphologywas analysed inWTand Zfp106−/− litter-
mates at 6- and 14-weeks of age (male, n = 3 per genotype).
For assessment of motor neuron survival, the animals were
terminally anaesthetized with 4.5% chlorohydrate (1 ml/100 g of
body weight), transcardially perfused with 4% PFA and the lum-
bar region of the spinal cord removed, post-ﬁxed in 4% PFA and
cryopreserved in 30% sucrose. Serial 20 μm transverse sections
were cut on a cryostat, stained with gallocyanin, a Nissl stain
(53) and the number of positively stained motor neurons in the
sciaticmotor pool of every third section between the L3 and L6 le-
vels of the spinal cord was counted, as previously described
(12,13). Only large, polygonal neurons with a clearly identiﬁable
nucleus and nucleolus were included in counts. This protocol
avoids the possibility of counting the same cells twice in con-
secutive sections. A total of 40 sectionswere examined per spinal
cord and at least ﬁve female mice were analysed from each ex-
perimental group.
For analysis of ventral and dorsal roots, DRG, and corticosp-
inal tracts animals were perfused transcardially with saline fol-
lowed with 3% glutaraldehyde in 0.05 M sodium cacodylate.
Right L4 and L5 DRG with the attached dorsal and ventral roots,
and spinal cords were dissected, post-ﬁxed in 1% osmium tetrox-
ide (Agar Scientiﬁc) and processed into araldite CY212 epoxy
resin (Agar Scientiﬁc) through graded alcohols and propylene
oxide using a standard protocol. Semi-thin sections (0.8 μm)
were cut on an Ultracut E ultra-microtome (Leica), stained with
1% toluidine blue containing 1% borax (BDH), and examined
with a Dialux light microscope. Neuronal morphology was ana-
lysed from 15-week-old WT and Zfp106−/− littermates (female,
n = 3 per genotype).
Axon morphology
Images of three semi-thin sections at P9 from lumbar L4 and L5
dorsal and ventral roots and sciatic nerve sections were selected
randomly per animal. Three animals per genotype were used. To
calculate axon diameter and g-ratios of myelinated axons, three
random regions from each picture were analysed. All myelinated
axons within each region were measured to calculate the g-ratio
and axon diameter. In total, approximately 40 axons within each
section andmore than 120 axons per animalwere analysed using
AxioVision LE Rel. 4.2 software. The examiner was blind to
genotype.
Electron microscopy
WT and Zfp106−/− littermates were perfused as above (3% glutar-
aldehyde in 0.05 M sodium cacodylate) and dorsal roots dis-
sected. Ultrathin sections 80 nm thick were cut from selected
areas of the tissue, stained with uranyl acetate and lead citrate,
and examined at 80 kV in a Philips CM10 electron microscope.
Images were taken using a Megaview 3 digital camera and Olym-
pus iTEM software. Morphology was analysed from 15-week-old
WT and Zfp106−/− littermates (female, n = 3 per genotype).
Immunocytochemistry
For the analysis of brain histopathology 15-week-old WT and
Zfp106−/−mice were perfused transcardially with saline followed
with 4% PFA, brain transferred to formalin and embedded in par-
afﬁnwax. Staining with H&E and anti- GFAP, IBA-1, p62, MBP and
neuroﬁlament antibodies was undertaken using a Ventana auto-
mated immunohistochemical stainingmachine (VentanaMedic-
al Systems, Tuscon, AZ, USA). Parafﬁn-embedded sections once
incubated with appropriate secondary antibodies were devel-
oped using 3,30-diaminobenzidine and counterstained with
haematoxylin.
Twenty micrometer transverse sections from the lumbar re-
gion of ﬁxed spinal cords collected onto glass slides were immu-
no-ﬂuorescently stained with anti-GFAP (Cy-conjugated mouse
monoclonal, Sigma; used at 1:1000) and anti-IBA1 (rabbit poly-
clonal, Abcam; used at 1:500), visualized using a secondary Alex-
aFluor488-conjugated antibody (Invitrogen) and counterstained
with NeuroTrace® 435⁄455 ﬂuorescent Nissl stain (Invitrogen). A
C-terminal p62 antibody (Progen, Germany; 1:300) was also
used to stain lumbar spinal cord sections. Confocal images
were taken using a Zeiss 710 microscope. Active cell death was
analysed using TUNEL staining (Promega) followingmanufactur-
er recommendations.
Immunoblot
Fresh frozen spinal cords from female mice at 6 and 16 weeks of
age were homogenized in RIPA buffer with protease inhibitors
(complete mini EDTA-free, Roche). After centrifuging the hom-
ogenate at 12 000×g at 4°, the supernatant was used for west-
ern-blot analysis using pre-cast SDS gels (Invitrogen). The
primary antibodies assessed included rabbit anti-actin (Sigma),
LC3II (Nanotools) and ZFP106 (Novus, Santa Cruz, Bethyl). The
Odyssey infrared imaging system (Li-Cor) was used for band de-
tection and quantiﬁcation.
RNA-seq
Whole spinal cords from male, 6-week old Zfp106tm1a(KOMP)Wtsi
mice (WT, n = 6; Zfp106−/−, n = 5) were homogenized and total
RNA extracted using an RNeasy ﬁbrous tissue extraction kit (Qia-
gen). RNA integrity was conﬁrmed and concentration measured
(∼0.2 mg/ml) using a Bioanalyzer (Agilent). cDNA libraries were
created from 5 μg total RNA as follows. Using a TruSeq RNA Sam-
ple Prep v2 kit (Illumina), poly-A tailed RNA (mRNA) was puriﬁed
from total RNA using an oligo dT magnetic bead pull-down. The
resulting mRNA was fragmented using metal ion-catalysed hy-
drolysis and random priming used to synthesize double-
stranded cDNA. End repair was performed with a combination
of ﬁll-in reactions and exonuclease activity to produce blunt
ends. A single ‘A’ base was added to blunt ends followed by liga-
tion to Illumina Paired-End Sequencing adapters containing un-
ique index sequences, allowing samples to be pooled. The
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resulting libraries were ampliﬁed through 10 cycles of PCR using
KAPAHiﬁ Polymerase, products were pooled based on a post-PCR
Agilent Bioanalyzer, then the pool was size-selected using the
LabChip XT Caliper (200–300 bp range). The multiplexed library
was sequenced on the Illumina HiSeq 2000 (75 bp paired-end
read length) aiming for >3 Gigabases of data per sample. Sequen-
cing reads were aligned against the NCBI build 37.2 of the Mus
musculus reference genome using the software TopHat (54). The
TopHat alignment incorporated the reference genes annotations
(GTF format) provided as part of the Illumina iGenomes project.
Duplicate readswere ﬁltered using the PICARD tools. Read counts
per gene and per exon were computed using the python scripts
provided with the DESeq/DEXSeq packages. Differential expres-
sion at the gene level was computed using the R package DESeq
(55) and at the exon level using the R package DEXSeq (56).
qPCR
Gene expression of Zfp106 from 6-week-old WT and Zfp106−/−
mice (female, n = 3 per genotype): ∼20–25 mg of brain or spinal
cordwashomogenized andRNAextractedusing aQiagenRNeasy
ﬁbrous tissue extraction kit. 200 ng of total RNA was used in a
10 μl reaction using the TaqMan RNA-to-CTOne Step kit (Applied
Biosystems). A TaqMan probe ﬂanking the Zfp106 splice acceptor
region was used with GAPDH as an endogenous control (Applied
Biosystems) in a multiplex primer-limited reaction. Reactions
were performed in triplicate on an ABI Viia7 qPCR machine and
analysed with Viia7 1.1 software. Gene expression data for
Zfp106−/− tissues were analysed using the ΔΔCTmethod and nor-
malized using GAPDH as endogenous reference gene (which ex-
pression is not changed by Zfp106 deﬁciency via RNA-seq, data
not shown) relative to WT tissues (57).
Northern blot
Total mRNAwas isolated from brains and spinal cords using the
Qiagen RNeasy lipid kit. RNA concentration was estimated using
Nanodrop (Thermo scientiﬁc). 3′UTR probes were cloned from
WT brain or spinal cord genomic DNA into a TOPO-TA (Invitrogen)
vector by PCR. Digoxigenin-labeled antisense RNA 3′UTR probes
were generated through in vitro transcription (Roche). RNA and an
RNA ladder (Invitrogen) were run on formaldehyde gels (Ambion)
for 2–3 h, then transferred upright for 4 h to N+ nylon membrane.
RNAwas crosslinked with a stratalinker, then the membrane was
pre-hybridized with Ambion hybridization solution at 68°C. Probe
was denatured and added to hybridization solution, and hybrid-
ization was carried out overnight. After membrane washings,
CDP-Star development solution was used to detect bound probe.
Membranes were exposed to X-ray ﬁlm and developed.
Embryonic motor neuron culture
Motor neuron cultures were prepared from WT, Zfp106+/− and
Zfp106−/− littermate embryos as previously described (58). Brieﬂy,
embryonic spinal cords (E13.5) were removed, ventral horns iso-
lated, motor neurons plated at 40 000 cells/cm2 onto cover-slips;
cover-slips were coated with 1.5 mg/ml polyornithine (Sigma Al-
drich) in sterile water for a minimum of 2 h followed with 1 mg/
ml laminin (Sigma Aldrich) in L-15 medium (Sigma Aldrich) for
2 h. Motor neurons were maintained in complete neurobasal me-
dium (CNB); 200 ml of which contains: 191 ml neurobasal me-
dium, 4 ml B27 supplement (1 unit/ml; Gibco), 4 ml horse serum
(PAA Laboratories), 500 µl 0.5 m -glutamine (Gibco), 100 µl
0.05% 2-mercaptoethanol (Gibco), 20 µl ciliarly neurotrophic factor
(CNTF; 500 pg/ml; Alomone Labs), 2 µl glial-derived neurotrophic
factor (GDNF; 100 pg/ml; Alomone Labs), 2 µl brain-derived neuro-
trophic factor (BDNF; 100 pg/ml), 2 ml P/S, in a 37°C, 5% CO2 hu-
midiﬁed incubator for a minimum of 7 days.
Mitochondrial function
Embryonic motor neurons (identiﬁed as having at least three pro-
cesses) were loaded for 40 min with 20 n TMRM (Molecular
Probes) in a HEPES-buffered salt solution (HBSS) composed (m):
156 NaCl, 3 KCl, 2MgSO4, 1.25 KH2PO4, 2 CaCl2, 10 glucose and 10
HEPES, pH adjusted to 7.3 with NaOH. The dye was present at the
same concentration in all solutions throughout the experiment.
TMRM measurements were made using a Zeiss 710 CLSM
equipped with a META detection system and a 40× oil immersion
objective. Illumination intensity was kept to a minimum (at 0.1–
0.2% of laser output) to avoid phototoxicity and the pinhole set
to give an optical slice of ∼2 μm. TMRM was excited using the
565 nm laser line and ﬂuorescence measured above 580. FAD++
autoﬂuorescencewas excited at 458 andmeasured at 510–530 nm.
The autoﬂuorescence ofNADH (andNAD(P)H) inmotor neuron
cultures was imaged using an epiﬂuorescence inverted micro-
scope equipped with a 40× ﬂuorite objective. Excitation light was
provided by a Xenon arc lamp, and the beam passed through a
monochromator (Cairn Research, UK). Emitted ﬂuorescence light
was reﬂected through a long-pass ﬁlter to a cooled CCD camera
(Retiga, QImaging, Canada) and digitized to 12 bit resolution. All
imaging data were collected and analysed using software from
Andor (UK). The blueautoﬂuorescence emitted by thepyridinenu-
cleotides NADH and NAD(P)H in their reduced form was excited
with a 360 nm and emission was measured at 435–485 nm.
For assessment of the redox state, the dynamic range of
NADH autoﬂuorescence was measured. The dynamic range of
the signals was deﬁned by obtaining the maximally oxidized sig-
nal following the response to 1 μ triﬂuorocarbonylcyanide phe-
nylhydrazone (FCCP, which stimulates maximal respiration and
fully oxidizes themitochondrial NADHpool). In these conditions,
mitochondrial NADH is taken as 0%. The maximally reduced sig-
nal was then deﬁned as the response to 1 m sodium cyanide
(NaCN) which fully inhibits respiration), preventing NADH oxida-
tion, and so promotingmaximal NADH reduction. In these condi-
tions, mitochondrial NADH is taken as 100%.
All data presented were obtained from at least ﬁve cover-slips
and two to three different cell preparations.
Statistical analysis
An ANOVA test was used to compare between WT, Zfp106+/− and
Zfp106−/− genotypes per time point followed by Bonferroni’smul-
tiple comparisons testing correction for weight, grip strength, ro-
tarod, open ﬁeld parameters distancemoved and velocity, soleus
muscle ﬁbre types, and mitochondrial data. The Mann–Whitney
test was used to compareWTwith Zfp106−/− littermates per time
point or Zfp106−/− cohorts between time points for TA and EDL
maximum muscle force, surviving motor units innervating the
EDL, FI and motor neuron survival. Cumulative frequencies for
axon distribution were compared using the Kolmogorov–Smir-
nov test. Two-tailed tests were used in all instances and signiﬁ-
cance level was set at P < 0.05.
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